News
ALLO
2.010
+2.03%
0.040
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Ultragenyx Pharmaceutical (RARE) and Allogene Therapeutics (ALLO)
TipRanks · 2d ago
Weekly Report: what happened at ALLO last week (0727-0731)?
Weekly Report · 4d ago
FDA Grants RMAT, Fast Track Status To Cema-cel For High-Risk Large B-cell Lymphoma; Stock Up
NASDAQ · 07/30 08:56
Analysts’ Top Healthcare Picks: Repligen (RGEN), Allogene Therapeutics (ALLO)
TipRanks · 07/29 18:00
Allogene rises as FDA offers Fast Track, RMAT tags to cell therapy
Seeking Alpha · 07/29 17:47
Allogene gets RMAT, Fast Track designations for cemacabtagene ansegedleucel
TipRanks · 07/29 12:56
Allogene Therapeutics' Cemacabtagene Ansegedleucel Receives FDA's Regenerative Medicine Advanced Therapy, Fast Track Designations To Treat B-Cell Lymphoma
Benzinga · 07/29 12:32
Insider Sellers Might Regret Selling Allogene Therapeutics Shares at a Lower Price Than Current Market Value
Simply Wall St · 07/29 10:45
Weekly Report: what happened at ALLO last week (0720-0724)?
Weekly Report · 07/27 09:44
Weekly Report: what happened at ALLO last week (0713-0717)?
Weekly Report · 07/20 09:42
Analysts Are Bullish on Top Healthcare Stocks: Tenax Therapeutics (TENX), Allogene Therapeutics (ALLO)
TipRanks · 07/15 17:50
Allogene publishes Phase 1 data in Journal of Clinical Oncology
TipRanks · 07/15 13:25
Allogene Therapeutics Publishes Data From Phase 1 TRAVERSE Trial Of ALLO-316 In Advanced Or Metastatic Renal Cell Carcinoma; Trial Shows 31% Confirmed Response Rate With Recommended Phase 2 Regimen; Robust Expansion And Tumor Infiltration Seen
Benzinga · 07/15 12:33
Weekly Report: what happened at ALLO last week (0706-0710)?
Weekly Report · 07/13 09:43
Citizens biotech analyst holds an analyst/industry conference call
TipRanks · 07/06 18:35
Weekly Report: what happened at ALLO last week (0629-0703)?
Weekly Report · 07/06 09:45
Allogene Therapeutics: A High-Upside Bet On The Next Wave Of CAR-T Innovation
Seeking Alpha · 07/04 14:10
Citizens biotech analysts hold an analyst/industry conference call
TipRanks · 07/02 19:25
Weekly Report: what happened at ALLO last week (0622-0626)?
Weekly Report · 06/29 09:42
Allogene Launches ATM Offering to Bolster Capital Flexibility
TipRanks · 06/22 20:54
More
Webull provides a variety of real-time ALLO stock news. You can receive the latest news about Allogene Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About ALLO
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. It is focused on three core programs: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID), and Renal Cell Carcinoma (RCC). It is developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and advanced proprietary T cell manufacturing technologies. Its product candidate, cemacabtagene ansegedleucel, referred to as cema-cel, is an engineered allogeneic CAR T cell product candidate that targets CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. It is focused on developing cema-cel for LBCL. Its pipeline also includes ALLO-316 and ALLO-329.